心膜炎薬の世界市場2019-2023

◆英語タイトル:Global Pericarditis Drugs Market 2019-2023
◆商品コード:IRTNTR31365
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年5月21日
◆ページ数:128
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:米州、アジア、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、心膜炎薬の世界市場について調べ、心膜炎薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、心膜炎薬の市場規模をセグメンテーション別(製品別(NSAID、コルヒチン、その他)、)と地域別(米州、アジア、ヨーロッパ(EMEA))に分けて算出しました。Technavio社は心膜炎薬の世界市場規模が2019-2023期間中に年平均4%成長すると予測しています。
・サマリー
・レポートの範囲
・心膜炎薬の市場状況
・心膜炎薬の市場規模
・心膜炎薬の市場予測
・心膜炎薬の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(NSAID、コルヒチン、その他)
・心膜炎薬の顧客状況
・主要地域別市場規模:米州、アジア、ヨーロッパ(EMEA)
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

About this market

The global pericarditis drugs market is currently witnessing a high patient pool seeking treatment for the disease. Pericarditis is the most commonly occurring disease of the pericardium. It is the cause for 5% of the total emergency visits to healthcare professionals for chest pain, whereas, in Western Hemisphere, idiopathic pericarditis is the underlying cause for more than 90% cases. Acute pericarditis is diagnosed in 90% cases and is idiopathic in nature, whereas the remaining 10% cases of the total pericarditis diagnosed patients are secondary to bacterial and viral infections, myocardial infarction, autoimmune diseases, uremia, cardiac surgery, trauma, radiation, and any malignancy. Thus, the rising prevalence of pericarditis increases the demand for pericarditis drugs, which drives market growth. Technavio’s analysts have predicted that the pericarditis drugs market will register a CAGR of over 4% by 2023. Technavio’s analysts have predicted that the pericarditis drugs market will register a CAGR of over 4% by 2023.

Market Overview

Increasing incidence of recurrent pericardial effusion post cardiac surgery

Recurrent pericardial effusion is the most common complication that occurs after cardiac surgery. Postpericardiotomy syndrome (PPS) is a medical condition that is characterized by the inflammation of the pericardium, which occurs after one to six weeks after surgical incision of the pericardium. Clinically, PPS is characterized by fever, eosinophilia, and pleuritis, and medication treatment involves the use of aspirin and other NSAIDs. In the last few years, colchicine has been evolved as a potent treatment option for recurrent pericardial effusion. The anti-inflammatory effect of colchicine is linked to the ability of the drug to bind with tubulin, resulting in inhibition of neutrophil motility and activity, thereby reducing the inflammation. Colchicine acts by suppressing or inhibiting various leukocytes and fibroblasts at the site of inflammation. Hence, the rising cases of PPS increase the demand for pericarditis drugs, which contributes to market growth.

Side effects associated with pericarditis drugs

The global pericarditis drugs market is predominantly led by NSAIDs and colchicine, owing to their therapeutic benefits. However, they are related to potential side effects. For instance, the US FDA had issued warnings on the use of NSAIDs, stating that they increase the risk of cardiovascular and cerebrovascular events in patients who had a history of coronary artery disease and are being simultaneously receiving NSAIDs. These adverse events are related to the long-term use of these drugs and their escalating dosage. Considering the side effects associated with pericarditis drugs, there is limited use of these drugs in patients with other comorbid cardiovascular diseases, which will hinder the growth prospects of the market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the pericarditis drugs market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented. The presence of several companies, including AstraZeneca Plc and Bayer AG makes the competitive environment quite intense. Factors such as the rising prevalence of pericarditis and the increasing incidence of recurrent pericardial effusion post cardiac surgery will provide considerable growth opportunities to the pericarditis drugs manufacturers. Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

NSAIDs – Market size and forecast 2018-2023

Colchicine – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

AstraZeneca Plc

Bayer AG

Johnson & Johnson Services Inc.

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global cardiovascular disorder treatment market

Exhibit 02: Segments of global cardiovascular disorder treatment market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Emerging trends in global pericarditis drugs market

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Market overview 2018

Exhibit 10: Analysis of global pericarditis drugs market 2018

Exhibit 11: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 12: Five forces analysis 2018

Exhibit 13: Five forces analysis 2023

Exhibit 14: Bargaining power of buyers

Exhibit 15: Bargaining power of suppliers

Exhibit 16: Threat of new entrants

Exhibit 17: Threat of substitutes

Exhibit 18: Threat of rivalry

Exhibit 19: Market condition – Five forces 2018

Exhibit 20: Product – Market share 2018-2023 (%)

Exhibit 21: Comparison by product

Exhibit 22: NSAIDs – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Treatment regime with NSAIDS for pericarditis

Exhibit 24: NSAIDs – Year-over-year growth 2019-2023 (%)

Exhibit 25: Colchicine – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: Colchicine – Year-over-year growth 2019-2023 (%)

Exhibit 27: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: Others – Year-over-year growth 2019-2023 (%)

Exhibit 29: Market opportunity by product

Exhibit 30: Customer landscape

Exhibit 31: Market share by geography 2018-2023 (%)

Exhibit 32: Geographic comparison

Exhibit 33: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Centers for Disease Control and Prevention (CDC) facts about heart disease

Exhibit 35: North America – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in North America

Exhibit 37: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in Europe

Exhibit 40: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 41: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 42: Top 3 countries in Asia

Exhibit 43: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 44: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 45: Top 3 countries in ROW

Exhibit 46: Key leading countries

Exhibit 47: Market opportunity

Exhibit 48: Side effects associated with use of NSAIDs

Exhibit 49: Renal impairment associated with use of NSAIDs

Exhibit 50: Impact of drivers and challenges

Exhibit 51: Geriatric population scenario in US 2017

Exhibit 52: Vendor landscape

Exhibit 53: Landscape disruption

Exhibit 54: Vendors covered

Exhibit 55: Vendor classification

Exhibit 56: Market positioning of vendors

Exhibit 57: AstraZeneca Plc – Vendor overview

Exhibit 58: AstraZeneca Plc – Product segments

Exhibit 59: AstraZeneca Plc – Organizational developments

Exhibit 60: AstraZeneca Plc – Geographic focus

Exhibit 61: AstraZeneca Plc – Key offerings

Exhibit 62: AstraZeneca Plc – Key customers

Exhibit 63: Bayer AG – Vendor overview

Exhibit 64: Bayer AG – Product segments

Exhibit 65: Bayer AG – Organizational developments

Exhibit 66: Bayer AG – Geographic focus

Exhibit 67: Bayer AG – Segment focus

Exhibit 68: Bayer AG – Key offerings

Exhibit 69: Bayer AG – Key customers

Exhibit 70: Johnson & Johnson Service, Inc. – Vendor overview

Exhibit 71: Johnson & Johnson Services, Inc. – Business segments

Exhibit 72: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 73: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 74: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 75: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 76: Johnson & Johnson Services, Inc. – Key customers

Exhibit 77: Pfizer Inc. – Vendor overview

Exhibit 78: Pfizer Inc. – Business segments

Exhibit 79: Pfizer Inc. – Organizational developments

Exhibit 80: Pfizer Inc. – Geographic focus

Exhibit 81: Pfizer Inc. – Segment focus

Exhibit 82: Pfizer Inc. – Key offerings

Exhibit 83: Pfizer Inc. – Key customers

Exhibit 84: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 85: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 86: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 87: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 88: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 89: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 90: Validation techniques employed for market sizing

Exhibit 91: Definition of market positioning of vendors



【掲載企業】

AstraZeneca Plc
Bayer AG
Johnson & Johnson Services Inc.
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[心膜炎薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆